Therefore, FES-PET/CT may be useful to assess the potential eligibility for anti-hormonal treatment in AGCT patients by noninvasively capturing the estrogen receptor expression levels of all separate tumor lesions. The gene discussed is ESR1; the disease is neoplasm.